摘要
目的:观察抗精神病药物喹硫平治疗甲基苯丙胺所致精神障碍的疗效及不良反应,并与利培酮对照。方法:将60例符合《中国精神疾病分类方案与诊断标准》第三版(CCMD-3)诊断的甲基苯丙胺所致精神障碍患者,随机分为两组:喹硫平组和利培酮组,每组各30例。两组分别用喹硫平片(最大剂量≤400mg·d-1)和利培酮(最大剂量≤400mg·d-1)治疗21d。采用《简明精神病评定量表》(BPRS)、《大体功能评定量表》(GAS)和《副反应量表》(TESS)评定患者的精神病症状、疗效和不良反应。结果:喹硫平组总有效率为90.0%,利培酮组为86.7%,两组比较差异无显著性(P>0.05)。与利培酮组比较,喹硫平组对焦虑抑郁、失眠控制较好,锥体外系症状较少,差异有显著性(P<0.05),其他不良反应两组差异无显著性。结论:喹硫平与利培酮疗效相当,但喹硫平对有些症状控制较好,有些不良反应较轻。
Objective：To observe the efficacy and adverse drug effects of quetiapine, an antipsychotics for the treatment of methamphetamine-induced psychiatric disorder. Methods：Sixty patients diagnosed with the CCMD-3 criteria as having methamphetamine-induced psychiatric disorder were randomly divided into quetiapine group（n=30） and risperidone group （n=30）. Both groups were treated with quetiapine or risperidone for 21 days. The largest doses for quetiapine and risperidone were ≤400 mg·d-1 and ≤4 mg·d -1, respectively. The efficacy was assessed with Brief Psychiatric Rating Scale（BPRS） and Global Assessment Scale（GAS）,and the adverse drug effects were assessed with Treatment Emergent Symptoms Scale（TESS）. Results：The effective rates of quetiapine group and risperidone group were 90.0% and 86.7%, respectively, which showed no difference between the two groups（P〉0.05）. Compared with risperidone, quetiapine had better control for anxiety, depression and insomnia, and indicated less extrapyramidal syndrome（P〈0.05）. Conclusion：Both quetiapine and risperidone are effective in the treatment of methamphetamine-induced psychiatric disorder,but quetiapine has better efficacy for some symptoms and some of its adverse effects are slighter.
出处
《中国药物依赖性杂志》
CAS
CSCD
2007年第6期435-437,共3页
Chinese Journal of Drug Dependence
关键词
喹硫平
利培酮
甲基苯丙胺
精神障碍
quetiapine
risperidone
methamphetamine
psychotic disorder
